Atara Biotherapeutics Target of Unusually High Options Trading (NASDAQ:ATRA)

Atara Biotherapeutics Inc (NASDAQ:ATRA) was the target of some unusual options trading on Thursday. Stock traders acquired 942 put options on the stock. This represents an increase of approximately 1,372% compared to the average volume of 64 put options.

In other news, CEO Isaac E. Ciechanover sold 2,200 shares of Atara Biotherapeutics stock in a transaction dated Friday, December 28th. The stock was sold at an average price of $15.15, for a total transaction of $33,330.00. Following the transaction, the chief executive officer now owns 743,675 shares in the company, valued at approximately $11,266,676.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Gad Soffer sold 7,000 shares of Atara Biotherapeutics stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $15.00, for a total value of $105,000.00. Following the transaction, the executive vice president now owns 166,342 shares in the company, valued at approximately $2,495,130. The disclosure for this sale can be found here. Insiders have sold a total of 264,088 shares of company stock worth $6,442,371 in the last quarter. 16.20% of the stock is currently owned by company insiders.

Several large investors have recently bought and sold shares of the business. Dimensional Fund Advisors LP increased its position in shares of Atara Biotherapeutics by 2.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 21,718 shares of the biotechnology company’s stock worth $304,000 after purchasing an additional 610 shares during the last quarter. Teachers Advisors LLC increased its position in shares of Atara Biotherapeutics by 2.4% during the 2nd quarter. Teachers Advisors LLC now owns 47,156 shares of the biotechnology company’s stock worth $660,000 after purchasing an additional 1,110 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Atara Biotherapeutics by 7.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock worth $285,000 after purchasing an additional 1,369 shares during the last quarter. Voya Investment Management LLC increased its position in shares of Atara Biotherapeutics by 16.2% during the 2nd quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock worth $165,000 after purchasing an additional 1,651 shares during the last quarter. Finally, Rhumbline Advisers increased its position in shares of Atara Biotherapeutics by 11.3% during the 2nd quarter. Rhumbline Advisers now owns 31,373 shares of the biotechnology company’s stock worth $439,000 after purchasing an additional 3,175 shares during the last quarter. 69.71% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities research analysts recently issued reports on the company. BidaskClub raised Atara Biotherapeutics from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, January 23rd. Cowen assumed coverage on Atara Biotherapeutics in a research report on Friday, January 26th. They issued an “outperform” rating on the stock. Goldman Sachs Group reissued a “neutral” rating and issued a $20.00 target price on shares of Atara Biotherapeutics in a research report on Friday, October 6th. ValuEngine raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Friday, December 29th. Finally, Canaccord Genuity reissued a “positive” rating and issued a $70.00 target price (up previously from $47.00) on shares of Atara Biotherapeutics in a research report on Friday, January 19th. Four investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. Atara Biotherapeutics presently has an average rating of “Buy” and an average price target of $30.60.

Atara Biotherapeutics (NASDAQ ATRA) traded down $2.50 during trading hours on Wednesday, hitting $37.75. The company’s stock had a trading volume of 981,807 shares, compared to its average volume of 1,393,767. The firm has a market cap of $1,400.45, a price-to-earnings ratio of -10.88 and a beta of 1.27. Atara Biotherapeutics has a 52-week low of $11.80 and a 52-week high of $40.75.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($1.02) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.97) by ($0.05). sell-side analysts predict that Atara Biotherapeutics will post -4 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/31/atara-biotherapeutics-sees-unusually-high-options-volume-atra.html.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply